PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Clinical Trials
5.0k
Trial Phases
6 Phases
Drug Approvals
69
Drug Approvals
Rimegepant Sulfate Orally Disintegrating Tablets
- Product Name
- 乐泰可
- Approval Number
- 国药准字HJ20240004
- Approval Date
- Jan 23, 2024
Ritlecitinib Tosylate Capsules
- Product Name
- 乐复诺
- Approval Number
- 国药准字HJ20230118
- Approval Date
- Oct 18, 2023
- Prev
- 1
- 2
- Next
Clinical Trials
Distribution across different clinical trial phases (3923 trials with phase data)• Click on a phase to view related trials
A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- First Posted Date
- 2025-10-22
- Last Posted Date
- 2025-10-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 200
- Registration Number
- NCT07219615
A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema
- Conditions
- Atopic DermatitisEczema, Atopic
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-10-14
- Last Posted Date
- 2025-10-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 200
- Registration Number
- NCT07216027
Study About Whether Atirmociclib/PF-07220060 Proportionally Increases Exposure as Dose Increases in Healthy Participants
- Conditions
- Healthy Volunteer
- Interventions
- Drug: atirmociclib (PF-07220060)
- First Posted Date
- 2025-10-10
- Last Posted Date
- 2025-10-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 72
- Registration Number
- NCT07215078
- Locations
- 🇺🇸
Pfizer Clinical Research Unit - New Haven, New Haven, Connecticut, United States
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
- Conditions
- Non-muscle Invasive Bladder Cancer
- Interventions
- First Posted Date
- 2025-10-03
- Last Posted Date
- 2025-10-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 294
- Registration Number
- NCT07206225
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸AdventHealth Orlando, Orlando, Florida, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
A Study to Learn if Multiple Doses of the Study Medicine Called Carbamazepine Changes How the Body Processes the Other Study Medicine PF-07248144
- First Posted Date
- 2025-09-30
- Last Posted Date
- 2025-09-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT07198035
- Locations
- 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Other, Belgium
- Prev
- 1
- 2
- 3
- 4
- 5
- 641
- Next
News
Flagship Pioneering Launches Expedition Medicines with $50M Investment in AI-Driven Covalent Drug Discovery
Flagship Pioneering has launched Expedition Medicines with a $50 million investment, focusing on AI-driven drug discovery for cancer and immune diseases using covalent chemistry principles.
Pfizer's BRAFTOVI Plus MEKTOVI Achieves Nearly Four-Year Survival in BRAF-Mutant Lung Cancer
Pfizer's BRAFTOVI plus MEKTOVI combination therapy demonstrated a median overall survival of 47.6 months in treatment-naïve patients with BRAF V600E-mutant metastatic non-small cell lung cancer.
Dovato Demonstrates Non-Inferior Efficacy to Biktarvy with Significantly Less Weight Gain in 96-Week HIV Treatment Study
ViiV Healthcare's PASO DOBLE trial shows Dovato (DTG/3TC) maintains viral suppression as effectively as Biktarvy (BIC/FTC/TAF) at 96 weeks in 553 virologically suppressed HIV-1 patients.
Activist Investor Shah Capital Calls for Novavax Sale Amid COVID Vaccine Market Share Struggles
Shah Capital, Novavax's second-largest shareholder with a 7.2% stake, has urged the company's board to pursue a sale, citing three consecutive years of poor COVID-19 vaccine performance.
Dublin Biotech Meta-Flux Raises €1.8M to Enhance Drug Development Accuracy with AI Platform
Dublin-based biotech Meta-Flux has secured €1.8 million in seed funding from senior executives at Pfizer, Merck, and Gilead Sciences to expand its AI-powered drug development platform.
Eli Lilly and AstraZeneca Emerge as Leading Candidates for Next Trump Administration Drug Pricing Deal
Wall Street analysts predict Eli Lilly and AstraZeneca are the most likely pharmaceutical companies to strike the next drug pricing deal with the Trump administration following Pfizer's September 29 agreement.
Nurix Therapeutics Advances Bexobrutideg Toward Pivotal CLL Trials with Strong Phase 1 Data
Nurix Therapeutics announced plans to initiate pivotal trials for bexobrutideg in relapsed/refractory chronic lymphocytic leukemia patients in the second half of 2025, including both accelerated approval and confirmatory Phase 3 studies.
Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer to Advance Oncology Pipeline
Zymeworks Inc. has appointed Dr. Adam Schayowitz as Acting Chief Development Officer to advance the company's broad portfolio of nominated product candidates and strengthen strategic partnerships.
COVID-19 Boosters Reduce Hospitalizations and Deaths by Up to 64% in Large Veterans Study
A large study of nearly 300,000 U.S. military veterans found that 2024-2025 COVID-19 mRNA boosters reduced emergency department visits by 29%, hospitalizations by 39%, and deaths by 64% compared to unvaccinated individuals.
Nilo Therapeutics Emerges from Stealth with $101 Million to Develop Neural Circuit-Based Immunomodulation Therapies
Nilo Therapeutics launched with $101 million Series A financing led by The Column Group, DCVC Bio, and Lux Capital to develop a new class of medicines targeting neural circuits in immune diseases.